FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004693485> ?p ?o ?g. }

• W3004693485 endingPage "78" @default.
• W3004693485 startingPage "70" @default.
• W3004693485 abstract "Background Paclitaxel-coated devices have been shown to decrease restenosis when used in the femoropopliteal artery. Recent reports have suggested a possible risk of increased late mortality in patients treated with paclitaxel. It has been suggested that younger patients and those with limited comorbidities may be at higher risk. Our objective was to analyze long-term mortality based on patient age comparing treatment with paclitaxel to uncoated devices. Methods We performed a retrospective review of 1,170 consecutive patients who underwent femoropopliteal percutaneous intervention by angioplasty, atherectomy, stent placement, or combination between 2011 and 2018. Patients were grouped by age at the time of procedure: <60 years old (n = 244, 20.9%), 60–80 years old (n = 635, 54.3%), and >80 years old (n = 291, 24.9%). Within each group, patients were further divided by use of paclitaxel. The primary outcome measure was survival assessed by Kaplan-Meier analysis. Differences between the groups were analyzed with analysis of variance. Multivariable analysis was performed using Cox proportional hazard models. Results Of the 1,170 patients who underwent femoropopliteal percutaneous intervention, 654 (55.9%) received a paclitaxel-coated device during treatment and 516 (44.1%) did not. Mean age of the overall patient cohort was 70.4 ± 12.6 years and 663 (56.7%) were male. When comparing the groups by age we found an increase in age but a decrease in the proportion of patients who smoke. The use of paclitaxel-coated devices was similar across the groups (<60 years old, 56.2%; 60–80 years old, 57.0%; >80 years old, 52.6%; P = 0.45). Demographics and comorbidities were similar between the patients treated with and without paclitaxel within each age group except more males in the <60-year-old group treated without paclitaxel and more patients with chronic limb threatening ischemia in the >80-year-old group treated with paclitaxel. In patients <60 and 60–80 years old paclitaxel use was associated with increased survival at 4 years: <60 (80.7% vs. 64.4%; P = 0.04); 60–80 (63.2% vs. 55.1%; P = 0.04). Survival was similar in the >80-year-old group (46.6% vs. 32.8%; P = 0.65). Conclusions Our data suggest that the use of paclitaxel-coated arterial devices is not associated with increased mortality. On the contrary, our data show that younger patients treated with paclitaxel show improved survival compared with those treated without paclitaxel. Paclitaxel-coated devices may be used with continued caution especially in patients at high risk for restenosis. Paclitaxel-coated devices have been shown to decrease restenosis when used in the femoropopliteal artery. Recent reports have suggested a possible risk of increased late mortality in patients treated with paclitaxel. It has been suggested that younger patients and those with limited comorbidities may be at higher risk. Our objective was to analyze long-term mortality based on patient age comparing treatment with paclitaxel to uncoated devices. We performed a retrospective review of 1,170 consecutive patients who underwent femoropopliteal percutaneous intervention by angioplasty, atherectomy, stent placement, or combination between 2011 and 2018. Patients were grouped by age at the time of procedure: <60 years old (n = 244, 20.9%), 60–80 years old (n = 635, 54.3%), and >80 years old (n = 291, 24.9%). Within each group, patients were further divided by use of paclitaxel. The primary outcome measure was survival assessed by Kaplan-Meier analysis. Differences between the groups were analyzed with analysis of variance. Multivariable analysis was performed using Cox proportional hazard models. Of the 1,170 patients who underwent femoropopliteal percutaneous intervention, 654 (55.9%) received a paclitaxel-coated device during treatment and 516 (44.1%) did not. Mean age of the overall patient cohort was 70.4 ± 12.6 years and 663 (56.7%) were male. When comparing the groups by age we found an increase in age but a decrease in the proportion of patients who smoke. The use of paclitaxel-coated devices was similar across the groups (<60 years old, 56.2%; 60–80 years old, 57.0%; >80 years old, 52.6%; P = 0.45). Demographics and comorbidities were similar between the patients treated with and without paclitaxel within each age group except more males in the <60-year-old group treated without paclitaxel and more patients with chronic limb threatening ischemia in the >80-year-old group treated with paclitaxel. In patients <60 and 60–80 years old paclitaxel use was associated with increased survival at 4 years: <60 (80.7% vs. 64.4%; P = 0.04); 60–80 (63.2% vs. 55.1%; P = 0.04). Survival was similar in the >80-year-old group (46.6% vs. 32.8%; P = 0.65). Our data suggest that the use of paclitaxel-coated arterial devices is not associated with increased mortality. On the contrary, our data show that younger patients treated with paclitaxel show improved survival compared with those treated without paclitaxel. Paclitaxel-coated devices may be used with continued caution especially in patients at high risk for restenosis." @default.
• W3004693485 created "2020-02-14" @default.
• W3004693485 creator A5000593874 @default.
• W3004693485 creator A5034555843 @default.
• W3004693485 creator A5035420010 @default.
• W3004693485 creator A5040420566 @default.
• W3004693485 creator A5047666745 @default.
• W3004693485 creator A5050133756 @default.
• W3004693485 creator A5050722849 @default.
• W3004693485 creator A5054009251 @default.
• W3004693485 creator A5064607335 @default.
• W3004693485 creator A5091743381 @default.
• W3004693485 date "2021-01-01" @default.
• W3004693485 modified "2023-09-27" @default.
• W3004693485 title "Paclitaxel-Coated Peripheral Arterial Devices are Associated with Reduced Mortality in Younger Patients" @default.
• W3004693485 cites W2118501388 @default.
• W3004693485 cites W2295508527 @default.
• W3004693485 cites W2509893127 @default.
• W3004693485 cites W2739447339 @default.
• W3004693485 cites W2782950511 @default.
• W3004693485 cites W2803839738 @default.
• W3004693485 cites W2895102032 @default.
• W3004693485 cites W2903350476 @default.
• W3004693485 cites W2913667111 @default.
• W3004693485 cites W2918814647 @default.
• W3004693485 cites W2945008422 @default.
• W3004693485 cites W2945286328 @default.
• W3004693485 cites W2946328497 @default.
• W3004693485 cites W2950779966 @default.
• W3004693485 cites W2969569683 @default.
• W3004693485 cites W2969976520 @default.
• W3004693485 cites W2972608884 @default.
• W3004693485 cites W2994764391 @default.
• W3004693485 cites W3005356742 @default.
• W3004693485 cites W3015601156 @default.
• W3004693485 cites W3023289929 @default.
• W3004693485 doi "https://doi.org/10.1016/j.avsg.2020.08.003" @default.
• W3004693485 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32795647" @default.
• W3004693485 hasPublicationYear "2021" @default.
• W3004693485 type Work @default.
• W3004693485 sameAs 3004693485 @default.
• W3004693485 citedByCount "3" @default.
• W3004693485 countsByYear W30046934852021 @default.
• W3004693485 countsByYear W30046934852022 @default.
• W3004693485 countsByYear W30046934852023 @default.
• W3004693485 crossrefType "journal-article" @default.
• W3004693485 hasAuthorship W3004693485A5000593874 @default.
• W3004693485 hasAuthorship W3004693485A5034555843 @default.
• W3004693485 hasAuthorship W3004693485A5035420010 @default.
• W3004693485 hasAuthorship W3004693485A5040420566 @default.
• W3004693485 hasAuthorship W3004693485A5047666745 @default.
• W3004693485 hasAuthorship W3004693485A5050133756 @default.
• W3004693485 hasAuthorship W3004693485A5050722849 @default.
• W3004693485 hasAuthorship W3004693485A5054009251 @default.
• W3004693485 hasAuthorship W3004693485A5064607335 @default.
• W3004693485 hasAuthorship W3004693485A5091743381 @default.
• W3004693485 hasConcept C126322002 @default.
• W3004693485 hasConcept C141071460 @default.
• W3004693485 hasConcept C167135981 @default.
• W3004693485 hasConcept C207103383 @default.
• W3004693485 hasConcept C2776694085 @default.
• W3004693485 hasConcept C2777209855 @default.
• W3004693485 hasConcept C2777292972 @default.
• W3004693485 hasConcept C2778283817 @default.
• W3004693485 hasConcept C2778583881 @default.
• W3004693485 hasConcept C2780326628 @default.
• W3004693485 hasConcept C2780813298 @default.
• W3004693485 hasConcept C44249647 @default.
• W3004693485 hasConcept C50382708 @default.
• W3004693485 hasConcept C71924100 @default.
• W3004693485 hasConcept C72563966 @default.
• W3004693485 hasConceptScore W3004693485C126322002 @default.
• W3004693485 hasConceptScore W3004693485C141071460 @default.
• W3004693485 hasConceptScore W3004693485C167135981 @default.
• W3004693485 hasConceptScore W3004693485C207103383 @default.
• W3004693485 hasConceptScore W3004693485C2776694085 @default.
• W3004693485 hasConceptScore W3004693485C2777209855 @default.
• W3004693485 hasConceptScore W3004693485C2777292972 @default.
• W3004693485 hasConceptScore W3004693485C2778283817 @default.
• W3004693485 hasConceptScore W3004693485C2778583881 @default.
• W3004693485 hasConceptScore W3004693485C2780326628 @default.
• W3004693485 hasConceptScore W3004693485C2780813298 @default.
• W3004693485 hasConceptScore W3004693485C44249647 @default.
• W3004693485 hasConceptScore W3004693485C50382708 @default.
• W3004693485 hasConceptScore W3004693485C71924100 @default.
• W3004693485 hasConceptScore W3004693485C72563966 @default.
• W3004693485 hasLocation W30046934851 @default.
• W3004693485 hasOpenAccess W3004693485 @default.
• W3004693485 hasPrimaryLocation W30046934851 @default.
• W3004693485 hasRelatedWork W1965479751 @default.
• W3004693485 hasRelatedWork W1969620714 @default.
• W3004693485 hasRelatedWork W1975874134 @default.
• W3004693485 hasRelatedWork W2036101787 @default.
• W3004693485 hasRelatedWork W2061673093 @default.
• W3004693485 hasRelatedWork W206307002 @default.
• W3004693485 hasRelatedWork W2109769695 @default.
• W3004693485 hasRelatedWork W2165115918 @default.
• W3004693485 hasRelatedWork W2397560180 @default.

• next